AUPHAurinia Pharmaceuticals Inc.
Price
+28%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, growing in the filings, the market undecided.
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $83M in Q2 2026 (quarter ended Jun 30, 2026), up 19% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $37M (45% of revenue). For the full year FY2025, revenue was $283M (+20% year on year) and net income $287M. Its largest product in Q2 2026 was License Collaboration And Royalty at $3.8M, 50.1% of the disclosed total, just ahead of Service at 49.9%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 19, 2026On August 19, 2026, Aurinia Pharmaceuticals Inc. (Aurinia or the Company) issued a press release announcing that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation …Other event · Form 8-K
- Aug 6, 2026Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.Earnings release · press release
- May 11, 2026As previously disclosed by Aurinia Pharmaceuticals Inc. (“Ultimate Parent” or “Aurinia”) in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation (“Parent”), entered into an Agreement and Plan of Merger (the …Acquisition or disposition completed · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $7.6MThe company’s own SEC segment disclosure.
- License Collaboration And Royalty$3.8M50%
- Service$3.8M50%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.